Evidence Snapshot

STE20-like serine/threonine-protein kinase

CHEMBL4202 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:28Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL4202

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats STE20-like serine/threonine-protein kinase as ChEMBL target CHEMBL4202, mapped to UniProt Q9H2G2. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

STE20-like serine/threonine-protein kinase

SINGLE PROTEIN · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL4202

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

Q9H2G2

STE20-like serine/threonine-protein kinase

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why STE20-like serine/threonine-protein kinase matters

As of 2026-09-14

STE20-like serine/threonine-protein kinase is reviewed as STE20-like serine/threonine-protein kinase (UniProt Q9H2G2); the current evidence base includes 25 approved drugs, 1458 compounds, and 275 assays, with lead potency reaching pChEMBL 10.7.

Protein context

STE20-like serine/threonine-protein kinase

STE20-like serine/threonine-protein kinase Sequence length is 1235 aa.

Review this target as STE20-like serine/threonine-protein kinase, mapped to UniProt Q9H2G2. Sequence length is 1235 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q9H2G2 Protein

Disease context

Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Activity base

Portfolio and assay base

ChEMBL currently tracks 25 approved drugs, 1458 compounds, and 275 assays for this target. The dominant activity type is KI. CHEMBL388978 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine

25 approved pChEMBL 10.7

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why STE20-like serine/threonine-protein kinase matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9H2G2, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1458

Total Compounds

275

Total Assays

Approved Drugs

IC50: 37.0, KI: 700.0, KD: 395.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL388978	10.7	Kd	—
No preferred name CHEMBL1230609	8.5	Kd	Clinical
No preferred name CHEMBL4875188	8.4	Ki	—
No preferred name CHEMBL4878325	8.4	Ki	—
No preferred name CHEMBL288441	8.3	Kd	Approved

Approved Drugs

Structure	Compound	First Approval
	ENTRECTINIB CHEMBL1983268	2019
	FEDRATINIB CHEMBL1287853	2019
	GILTERITINIB CHEMBL3301622	2018
	NERATINIB CHEMBL180022	2017
	MIDOSTAURIN CHEMBL608533	2017
	NINTEDANIB CHEMBL502835	2014
	BOSUTINIB CHEMBL288441	2012
	AXITINIB CHEMBL1289926	2012
	CRIZOTINIB CHEMBL601719	2011
	VANDETANIB CHEMBL24828	2011
	PAZOPANIB CHEMBL477772	2009
	SUNITINIB CHEMBL535	2006
	DASATINIB CHEMBL5416410	2006
	SORAFENIB CHEMBL1336	2005
	ERLOTINIB CHEMBL553	2004
	GEFITINIB CHEMBL939	2003

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:28Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 14, 2026, 12:22 PM KST As of · Sep 14, 2026

ChEMBL ChEMBL 36 CHEMBL4202